Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors
The purpose of this study is to:

1. Evaluate how the body reacts to sorafenib when taken daily in combination with paclitaxel and carboplatin,
2. Measure the blood levels of sorafenib, paclitaxel and carboplatin at specific times after taking the medication, and
3. To determine the safety of sorafenib.
Neoplasms
DRUG: Nexavar (Sorafenib, BAY43-9006)
Safety and pharmacokinetics of the three agents: sorafenib administered daily, without a break in dosing, in combination with carboplatin and paclitaxel, administered every 3 weeks, 2 years
To determine the safety profile and pharmacokinetics of oral sorafenib daily in combination with every 3-weekly carboplatin and paclitaxel., 2 years
The purpose of this study is to:

1. Evaluate how the body reacts to sorafenib when taken daily in combination with paclitaxel and carboplatin,
2. Measure the blood levels of sorafenib, paclitaxel and carboplatin at specific times after taking the medication, and
3. To determine the safety of sorafenib.